Der blev ikke set klinisk relevante forskelle i sikkerhedsprofilen for ALIMTA plus cisplatin inden for de histologiske undergrupper.
There were no clinically relevant differences observed for the safety profile of ALIMTA plus cisplatin within the histology subgroups.